secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cidara Therapeutics, Inc. (—)
CIK:        0001610618
Form:       8-K/A
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001610618-24-000054
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cidara sells rezafungin assets to NAPP; $11.145M advance forgiven, $2.786M milestone paid
--------------------------------------------------------------------------------

- On April 24, 2024, Cidara sold all rezafungin acetate assets (IP, regulatory approvals, milestone/royalty rights) to NAPP Pharmaceutical Group (Mundipharma affiliate).
- Mundipharma agreed to forgive an $11.145 million development milestone advance, conditional on completion of transition services and know-how transfer.
- Mundipharma paid Cidara a $2.786 million milestone upon UK approval of rezafungin for invasive candidiasis in adults.
- Cidara will provide transition services for up to 75 days; NAPP assumes costs of ongoing Phase 3 ReSPECT and China ReSTORE trials.
- Cidara enters a 7-year non-compete on developing, manufacturing, or commercializing any echinocandin antifungal product worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610618/000161061824000054/0001610618-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610618/000161061824000054/cdtx-20240423.htm
  HTML page:      https://secwatch.observer/filing/0001610618-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer